Developing novel blood-based biomarkers for Alzheimer's disease

Alzheimer's and Dementia

Volumn 10, Issue 1, 2014, Pages 109-114

  Snyder, Heather M ^a   Carrillo, Maria C ^a   Grodstein, Francine ^b   Henriksen, Kim ^c   Jeromin, Andreas ^d   Lovestone, Simon ^e   Mielke, Michelle M ^f   O'Bryant, Sid ^g   Sarasa, Manual ^h   Sjøgren, Magnus ⁱ   Soares, Holly ^j   Teeling, Jessica ^k   Trushina, Eugenia ^f   Ward, Malcolm ^l   West, Tim ^m   Bain, Lisa J ⁿ   Shineman, Diana W ^o   Weiner, Michael ^p,q   Fillit, Howard M ^o  

^a ALZHEIMER'S ASSOCIATION   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NORDIC BIOSCIENCE A S   (Denmark)

^d NextGen Sciences Dx   (United States)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f MAYO CLINIC   (United States)

^g University of North Texas Health Science Center   (United States)

^h Araclon Biotech   (Spain)

ⁱ DiaGenic ASA   (Norway)

^j BRISTOL MYERS SQUIBB   (United States)

^k UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^l Proteome Sciences Plc   (United Kingdom)

^m C2N Diagnostics   (United States)

ⁿ Independent Science Writer   (United States)

^o Alzheimers Drug Discovery Foundation   (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

^q SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

Alzheimer's disease; Biomarker; Blood based biomarker; Diagnostics; Early detection; Early diagnosis

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; BLOOD VESSEL INJURY; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; INFLAMMATION; NERVOUS SYSTEM INJURY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ALZHEIMER'S DISEASE; BIOMARKER; BLOOD BASED BIOMARKER; DIAGNOSTICS; EARLY DETECTION; EARLY DIAGNOSIS;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DISEASE PROGRESSION; EARLY DIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS;

EID: 84891073424     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.10.007     Document Type: Article

References (48)

1. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, R.C. Petersen, M.W. Weiner, and P.S. Aisen et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers Lancet Neurol 12 2013 207 216
2. A.D. Watt, K.A. Perez, A.R. Rembach, C.L. Masters, V.L. Villemagne, and K.J. Barnham Variability in blood-based amyloid-beta assays: the need for consensus on pre-analytical processing J Alzheimers Dis 30 2012 323 336
3. M. Thambisetty, and S. Lovestone Blood-based biomarkers of Alzheimer's disease: challenging but feasible Biomark Med 4 2010 65 79
4. A. Koyama, O.I. Okereke, T. Yang, D. Blacker, D.J. Selkoe, and F. Grodstein Plasma amyloid-beta as a predictor of dementia and cognitive decline: a systematic review and meta-analysis Arch Neurol 69 2012 824 831
5. J.B. Toledo, H. Vanderstichele, M. Figurski, P.S. Aisen, R.C. Petersen, and M.W. Weiner et al. Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI Acta Neuropathol 122 2011 401 413
6. Y. Gu, N. Schupf, S.A. Cosentino, J.A. Luchsinger, and N. Scarmeas Nutrient intake and plasma beta-amyloid Neurology 78 2012 1832 1840
7. V. Perez, L. Sarasa, J.A. Allue, D. Casabona, M. Montanes, and D. Insua et al. Beta-amyloid-17 is a major beta-amyloid fragment isoform in cerebrospinal fluid and blood that shows diagnostic value Alzheimers Dement 8 4 suppl 2012 P2 40
8. E. Portelius, R.A. Dean, M.K. Gustavsson, U. Andreasson, H. Zetterberg, and E. Siemers et al. A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease Alzheimers Res Ther 2 2010 7
9. V. Perez-Grijalba, P. Pesini, I. Monleon, M. Boada, L. Tarraga, and A. Ruiz-Laza et al. Biomarkers from the amyloid-beta pool in blood are associated with an increased likelihood of suffering from mild cognitive impairment J Alzheimers Dis 36 2013 211 219
10. E.S. Oh, M.M. Mielke, P.B. Rosenberg, A. Jain, N.S. Fedarko, and C.G. Lyketsos et al. Comparison of conventional ELISA with electrochemiluminescence technology for detection of amyloid-beta in plasma J Alzheimers Dis 21 2010 769 773
11. K. Henriksen, Y. Wang, M.G. Sorensen, N. Barascuk, J. Suhy, and K.L., Duffin et al. An enzyme-generated fragment of tau measured in serum shows an inverse-correlation to cognitive function PLoS One 8 2013 e64990
12. C. Randall, L. Mosconi, M. de Leon, and L. Glodzik Cerebrospinal fluid biomarkers of Alzheimer's disease in cognitively healthy elderly Front Biosci 18 2013 1150 1173
13. M.T. Heneka, M.K. O'Banion, D. Terwel, and M.P. Kummer Neuroinflammatory processes in Alzheimer's disease J Neural Transm 117 2010 919 947
14. V.H. Perry, and J. Teeling Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration Semin Immunopathol 35 2013 601 612
15. C. Holmes, C. Cunningham, E. Zotova, J. Woolford, C. Dean, and S. Kerr et al. Systemic inflammation and disease progression in Alzheimer disease Neurology 73 2009 768 774
16. C. Laske, M. Schmohl, T. Leyhe, E. Stransky, W. Maetzler, and D. Berg et al. Immune profiling in blood identifies sTNF-R1 performing comparably well as biomarker panels for classification of Alzheimer's disease patients J Alzheimers Dis 34 2013 367 375
17. A. Serrano-Pozo, M.P. Frosch, E. Masliah, and B.T. Hyman Neuropathological alterations in Alzheimer disease Cold Spring Harb Perspect Med 1 2011 a006189
18. M.M. Mielke, and C.G. Lyketsos Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets? Neuromolecular Med 12 2010 331 340
19. M.M. Mielke, V.V. Bandaru, N.J. Haughey, P.V. Rabins, C.G. Lyketsos, and M.C. Carlson Serum sphingomyelins and ceramides are early predictors of memory impairment Neurobiol Aging 31 2010 17 24
20. M.M. Mielke, N.J. Haughey, V.V. Ratnam Bandaru, S. Schech, R. Carrick, and M.C. Carlson et al. Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss Alzheimers Dement 6 2010 378 385
21. G. Zuliani, M. Cavalieri, M. Galvani, A. Passaro, M.R. Munari, and C. Bosi et al. Markers of endothelial dysfunction in older subjects with late onset Alzheimer's disease or vascular dementia J Neurol Sci 272 2008 164 170
22. S.E. O'Bryant, G. Xiao, R. Barber, J. Reisch, R. Doody, and T. Fairchild et al. A serum protein-based algorithm for the detection of Alzheimer disease Arch Neurol 67 2010 1077 1081
23. S.E. O'Bryant, G. Xiao, R. Barber, R. Huebinger, K. Wilhelmsen, and M. Edwards et al. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI PLoS One 6 2011 e28092
24. S.E. O'Bryant, G. Xiao, R. Barber, J. Reisch, J. Hall, and C.M. Cullum et al. A blood-based algorithm for the detection of Alzheimer's disease Dement Geriatr Cogn Disord 32 2011 55 62
25. S. Ray, M. Britschgi, C. Herbert, Y. Takeda-Uchimura, A. Boxer, and K. Blennow et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins Nat Med 13 2007 1359 1362 (Pubitemid 350073592)
26. C. Laske, T. Leyhe, E. Stransky, N. Hoffmann, A.J. Fallgatter, and J. Dietzsch Identification of a blood-based biomarker panel for classification of Alzheimer's disease Int J Neuropsychopharmacol 14 2011 1147 1155
27. H.D. Soares, W.Z. Potter, E. Pickering, M. Kuhn, F.W. Immermann, and D.M. Shera et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease Arch Neurol 69 2012 1310 1317
28. O'Brien D, Lovestone S, Kuhn K, Schulz-Knappe P, Ward M, Byers H., Pike I. Tandem mass tags and MRM mass spectrometry for the evaluation of biomarkers implicated in Alzheimer's disease. In: MP309 Proceedings of the 56th American Society of Mass Spectrometry conference. Denver, CO; 2008:55.
29. H.D. Soares, Y. Chen, M. Sabbagh, A. Roher, E. Schrijvers, and M. Breteler Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels Ann N Y Acad Sci 1180 2009 56 67
30. M. Thambisetty, A. Simmons, A. Hye, J. Campbell, E. Westman, and Y. Zhang et al. Plasma biomarkers of brain atrophy in Alzheimer's disease PLoS One 6 2011 e28527
31. P.F. Sullivan, C. Fan, and C.M. Perou Evaluating the comparability of gene expression in blood and brain Am J Med Genet B Neuropsychiatr Genet 141B 2006 261 268
32. P. Fehlbaum-Beurdeley, O. Sol, L. Desire, J. Touchon, T. Dantoine, and M. Vercelletto et al. Validation of AclarusDx, a blood-based transcriptomic signature for the diagnosis of Alzheimer's disease J Alzheimers Dis 32 2012 169 181
33. P.D. Rye, B.B. Booij, G. Grave, T. Lindahl, L. Kristiansen, and H.M. Andersen et al. A novel blood test for the early detection of Alzheimer's disease J Alzheimers Dis 23 2011 121 129
34. Y. Wang, M.G. Sorensen, Q. Zheng, C. Zhang, M.A. Karsdal, and K. Henriksen Will posttranslational modifications of brain proteins provide novel serological markers for dementias? Int J Alzheimers Dis 2012 2012 209409
35. A.D. Roses An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease Arch Neurol 67 2010 536 541
36. M.S. Chong, L.K. Goh, W.S. Lim, M. Chan, L. Tay, and G. Chen et al. Gene expression profiling of peripheral blood leukocytes shows consistent longitudinal downregulation of TOMM40 and upregulation of KIR2DL5A, PLOD1, and SLC2A8 among fast progressors in early Alzheimer's disease J Alzheimers Dis 34 2013 399 405
37. J.C. Lambert, S. Heath, G. Even, D. Campion, K. Sleegers, and M. Hiltunen et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease Nat Genet 41 2009 1094 1099
38. E. Silajdzic, L. Minthon, M. Bjorkqvist, and O. Hansson No diagnostic value of plasma clusterin in Alzheimer's disease PLoS One 7 2012 e50237
39. E.M. Schrijvers, P.J. Koudstaal, A. Hofman, and M.M. Breteler Plasma clusterin and the risk of Alzheimer disease JAMA 305 2011 1322 1326
40. F. Song, A. Poljak, J. Crawford, N.A. Kochan, W. Wen, and B. Cameron et al. Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals PLoS One 7 2012 e34078
41. M. Thambisetty, A. Simmons, L. Velayudhan, A. Hye, J. Campbell, and Y. Zhang et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease Arch Gen Psychiatry 67 2010 739 748
42. M. Thambisetty, Y. An, A. Kinsey, D. Koka, M. Saleem, and A. Guntert et al. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment Neuroimage 59 2012 212 217
43. L. IJsselstijn, L.J. Dekker, P.J. Koudstaal, A. Hofman, P.A. Sillevis Smitt, and M.M. Breteler et al. Serum clusterin levels are not increased in presymptomatic Alzheimer's disease J Proteome Res 10 2011 2006 2010
44. E. Trushina, T. Dutta, X.-M.T. Persson, M.M. Mielke, and R.C. Petersen Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics PLoS One 8 2013; e63644
45. Y. Sato, I. Suzuki, T. Nakamura, F. Bernier, K. Aoshima, and Y. Oda Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology J Lipid Res 53 2012 567 576
46. E. Nagele, M. Han, C. Demarshall, B. Belinka, and R. Nagele Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera PLoS One 6 2011 e23112
47. K. Henriksen, S. O'Bryant, H. Hampel, J. Trojanowki, T. Montine, and A. Jeromin et al. The future of blood-based biomarkers for Alzheimer's disease Alzheimers Dement 2013 10,1016/jjalz.20123.01.013 [Epub ahead of print]
48. M.C. Carrillo, K. Blennow, H. Soares, P. Lewczuk, N. Mattsson, and P. Oberoi et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium Alzheimers Dement 9 2013 137 140